Table 2.
Circulating factors before and after 20 wk of gonadotropin-releasing hormone agonist plus PL or E2 add-back therapy
| GnRHAG + PL, n = 15 |
GnRHAG + E2, n = 15 |
|||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Before intervention | After intervention | Within-group change (95% CI) | Before intervention | After intervention | Within-group change (95% CI) | Between-group difference in change* (95% CI) | P value |
| E2, pg/ml | 77.9 ± 17.4 | 23.2 ± 2.6 | −54.7 (−92.9, −16.4) | 70.6 ± 12.4 | 105 ± 30.4 | 34.1 (−42.8, 110.9) | −80.1 (−141, −19) | 0.01 |
| Estrone, pg/ml | 51.2 ± 5.0 | 39.9 ± 8.0 | −11.3 (−24.5, 1.8) | 55.0 ± 4.0 | 65.2 ± 7.6 | 10.2 (−8.7, 29.1) | −23.0 (−44.7, −1.3) | 0.04 |
| Progesterone, ng/ml | 0.52 ± 0.11 | 0.31 ± 0.05 | −0.21 (−0.45, 0.04) | 0.59 ± 0.09 | 0.33 ± 0.05 | −0.26 (−0.46, −0.06) | −0.01 (−0.16, 0.15) | 0.92 |
| Testosterone, ng/dl | 29.9 ± 5.1 | 25.6 ± 5.5 | −4.5 (−8.9, −0.1) | 32.7 ± 2.8 | 30.1 ± 3.2 | −3.8 (−7.9, 0.3) | −0.9 (−6.8, 5.0) | 0.75 |
| SHBG, nmol/l | 54.7 ± 7.2 | 46.3 ± 6.5 | −8.4 (−18.2, 1.4) | 40.9 ± 4.6 | 41.9 ± 5.8 | 0.9 (−4.3, 6.1) | −6.5 (−17.4, 4.3) | 0.23 |
| CBG, µg/ml | 25.5 ± 1.0 | 26.2 ± 1.0 | 0.7 (−0.7, 2.0) | 25.4 ± 0.9 | 25.4 ± 1.0 | −0.0 (−1.7, 1.7) | 0.7 (−1.3, 2.7) | 0.49 |
| Free cortisol, ng/ml | 3.3 ± 1.2 | 2.3 ± 0.6 | −1.1 (−4.0, 1.9) | 1.8 ± 0.6 | 2.4 ± 0.7 | 0.6 (−1.1, 2.2) | −0.2 (−2.2, 1.9) | 0.86 |
Values are means ± SE or mean (95% CI). n = no. of participants. CBG, corticosteroid-binding globulin; CI, confidence interval; E2, estradiol; GnRHAG, gonadotropin-releasing hormone agonist; PL, placebo; SHBG, sex hormone-binding globulin. SI unit conversions: estradiol pg/ml × 3.671 = pmol/l, estrone pg/ml × 3.699 = pmol/l, progesterone ng/ml × 3.18 = nmol/l, testosterone ng/dl × 0.0347 nmol/l, cortisol ng/ml × 2.76 = nmol/l, CBG µg/ml × 17.18 nmol/l.
*
Difference in change is group difference in change controlling for before intervention value.